Charles Schwab Investment Management Inc. Purchases 1,235 Shares of MBX Biosciences, Inc. $MBX

Charles Schwab Investment Management Inc. raised its position in shares of MBX Biosciences, Inc. (NYSE:MBX) by 1.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 94,546 shares of the company’s stock after acquiring an additional 1,235 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.28% of MBX Biosciences worth $698,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Nuveen Asset Management LLC bought a new stake in shares of MBX Biosciences during the fourth quarter worth approximately $267,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of MBX Biosciences in the fourth quarter valued at approximately $117,000. Citadel Advisors LLC boosted its stake in shares of MBX Biosciences by 62.5% in the fourth quarter. Citadel Advisors LLC now owns 220,330 shares of the company’s stock valued at $4,061,000 after buying an additional 84,722 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of MBX Biosciences in the fourth quarter valued at approximately $27,000. Finally, Deutsche Bank AG bought a new stake in shares of MBX Biosciences in the fourth quarter valued at approximately $80,000.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Oppenheimer assumed coverage on MBX Biosciences in a research note on Wednesday, July 16th. They set an “outperform” rating and a $38.00 target price for the company. Mizuho assumed coverage on MBX Biosciences in a research note on Tuesday, August 5th. They set an “outperform” rating and a $38.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $37.63.

MBX Biosciences Stock Down 3.4%

NYSE MBX opened at $14.57 on Wednesday. The company has a market capitalization of $489.46 million and a price-to-earnings ratio of -3.21. MBX Biosciences, Inc. has a twelve month low of $4.81 and a twelve month high of $27.50. The stock has a fifty day simple moving average of $13.13 and a 200 day simple moving average of $10.94.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.